18 May 2026 Recon: FDA names new acting CDER, CBER heads; Supreme Court denies pharma’s challenge to IRA price negotiations Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
14 May 2026 Recon: FDA upheaval prompts some biotechs to move early trials abroad; AZ’s Imfinzi combo boosts bladder cancer survival in late-stage trial Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
13 May 2026 IMDRF releases guidance on choosing and evaluating suppliers The International Medical Device Regulators Forum (IMDRF) has released a guidance for manufacturers on how to choose, evaluate, and monitor suppliers throughout the life cycle of medical devices. Regulatory News
12 May 2026 Recon: Makary to resign as FDA commissioner; EU reaches draft deal on Critical Medicines Act Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
11 May 2026 Recon: Makary’s fate as FDA commissioner up in the air; Roche to buy PathAI for $750M Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
07 May 2026 Recon: FDA to reconsider Atara, Pierre Fabre drug after surprise rejection; Amazon to stock Ozempic at US kiosks Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
05 May 2026 Recon: Kennedy urges Americans to quit SSRIs; BioNTech to scale back production, cut 1,860 jobs Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
04 May 2026 Recon: Amgen plans $300M manufacturing expansion in Puerto Rico; France fines Novo, Lilly over weight-loss drug ads Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
30 Apr 2026 Recon: FDA approves Axsome drug to treat agitation in Alzheimer’s patients; HHS appeals ruling on Kennedy’s vaccine policies Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing. Recon
28 Apr 2026 Recon: Supreme Court to consider skinny labeling case; Opioid settlement likely after Purdue Pharma sentencing Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing Recon